128 results
Page 2 of 7
8-K
EX-10.1
k1tp2bi7 bj4ijnxnycf
11 Apr 23
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
8:08am
S-4
tj16d8af5stohv5zqq
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm
8-K
EX-10.1
bb6av6aknyq zf
20 Dec 22
Entry into a Material Definitive Agreement
4:05pm
8-K
EX-99.1
esvplm34 kgymtv1ld
8 Nov 22
Adaptimmune Reports Third-Quarter Financial Results and Business Update
7:42am
8-K
EX-99.1
zbezzh6xsbtd5b8t5j
4 Aug 22
Adaptimmune Reports Second-Quarter Financial Results and Business Update
7:36am
8-K
EX-99.1
rxg0j4frqn82k 5cb3k9
9 May 22
Adaptimmune Reports First Quarter Financial Results and Business Update
7:40am
8-K
EX-10.1
93xiq
4 May 22
Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer
8:20am
424B5
25nr1fvsyxb
28 Apr 22
Prospectus supplement for primary offering
8:09am
8-K
EX-99.1
q5dm17fxcgz1
14 Mar 22
Adaptimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Business Update
8:06am
8-K
EX-10.01
ndxk7i
26 Jan 22
Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer
8:05am